Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi to Strengthen Marketing of Omnipaque in Outpatient Care
September 6, 2004
- BUSINESS NEWS IN BRIEF
September 6, 2004
- Norvasc Was Japan's Top-selling Drug in April-June: IMS Japan
September 6, 2004
- Amended GMP GL at the Final Stage of Preparation
September 6, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 6, 2004
- Wholesale Industry Should Standardize Ordering Systems: Kuraya Sanseido
August 30, 2004
- Korosho to Beef Up Drug Safety Measures: Dr Kurokawa
August 30, 2004
- Moroo Aims at 30% Market Share in Hokkaido
August 30, 2004
- REGULATORY NEWS IN BRIEF
August 30, 2004
- Towa to Use Pharmaceutical Technologies to Win Competition
August 30, 2004
- Sumitomo Pharm Focuses on 3 Fields of Drug Discovery
August 30, 2004
- Research Group Calls For Further Promotion of Generics
August 30, 2004
- Lipovas Lowers Stroke Risk by 25%: JAS Meeting
August 30, 2004
- Nichi-iko, Maruko to Form Business Tie-up
August 30, 2004
- TUT to Initiate Entrepreneur Program
August 30, 2004
- Toyobo to Embark on Contract Manufacturing in Earnest
August 30, 2004
- Iryo Proverbs Reveal Japanese Spirit (22)
August 30, 2004
- MBL, OTS Create Joint Venture to Develop Antibody Drugs
August 30, 2004
- Vitamins D3, K2 Are Second Choice Drugs for Steroid-induced Osteoporosis: GL
August 30, 2004
- JPMA to Survey Environment for Clinical Trials in Asia
August 30, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…